107 related articles for article (PubMed ID: 9549645)
1. Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and women.
Suri A; Forbes WP; Bramer SL
J Clin Pharmacol; 1998 Feb; 38(2):144-50. PubMed ID: 9549645
[TBL] [Abstract][Full Text] [Related]
2. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
Bramer SL; Forbes WP; Mallikaarjun S
Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
[TBL] [Abstract][Full Text] [Related]
3. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
Bramer SL; Forbes WP
Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
[TBL] [Abstract][Full Text] [Related]
4. Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers.
Bramer SL; Brisson J; Corey AE; Mallikaarjun S
Clin Pharmacokinet; 1999; 37 Suppl 2():69-77. PubMed ID: 10702889
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
Bramer SL; Suri A
Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
[TBL] [Abstract][Full Text] [Related]
6. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites.
Mallikaarjun S; Forbes WP; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():33-40. PubMed ID: 10702885
[TBL] [Abstract][Full Text] [Related]
7. Effect of omeprazole on the metabolism of cilostazol.
Suri A; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():53-9. PubMed ID: 10702887
[TBL] [Abstract][Full Text] [Related]
8. Effects of CYP3A inhibition on the metabolism of cilostazol.
Suri A; Forbes WP; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():61-8. PubMed ID: 10702888
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans.
Woo SK; Kang WK; Kwon KI
Clin Pharmacol Ther; 2002 Apr; 71(4):246-52. PubMed ID: 11956507
[TBL] [Abstract][Full Text] [Related]
10. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol.
Bramer SL; Forbes WP
Clin Pharmacokinet; 1999; 37 Suppl 2():25-32. PubMed ID: 10702884
[TBL] [Abstract][Full Text] [Related]
11. Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin.
Mallikaarjun S; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():79-86. PubMed ID: 10702890
[TBL] [Abstract][Full Text] [Related]
12. Interaction potential and tolerability of the coadministration of cilostazol and aspirin.
Mallikaarjun S; Forbes WP; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():87-93. PubMed ID: 10702891
[TBL] [Abstract][Full Text] [Related]
13. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication.
Dawson DL; Zheng Q; Worthy SA; Charles B; Bradley DV
Angiology; 2002; 53(5):509-20. PubMed ID: 12365857
[TBL] [Abstract][Full Text] [Related]
14. Potential interactions between cilostazol and probucol: a two-part, single-dose, open-label study in healthy Korean male volunteers.
Kim KP; Kim BH; Lim KS; Kim TE; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Oct; 31(10):2098-106. PubMed ID: 19922880
[TBL] [Abstract][Full Text] [Related]
15. Effects of cilostazol on arterial wound healing: a retrospective analysis.
Resnick KA; Gordon IL
Ann Vasc Surg; 2014 Aug; 28(6):1513-21. PubMed ID: 24561209
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic analysis of diurnal and seasonal variations of plasma concentrations of cilostazol in healthy volunteers.
Lee D; Son H; Lim LA; Park K
Ther Drug Monit; 2014 Dec; 36(6):771-80. PubMed ID: 24739664
[TBL] [Abstract][Full Text] [Related]
17. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication.
Wang T; Elam MB; Forbes WP; Zhong J; Nakajima K
Atherosclerosis; 2003 Dec; 171(2):337-42. PubMed ID: 14644405
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
19. Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats.
Lim TH; Cho YA; Choi DH
J Physiol Pharmacol; 2015 Aug; 66(4):591-7. PubMed ID: 26348083
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects.
Yoo HD; Park SA; Cho HY; Lee YB
Clin Pharmacol Ther; 2009 Sep; 86(3):281-4. PubMed ID: 19516253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
